2,862 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Keybank National Association OH

Keybank National Association OH bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,862 shares of the biopharmaceutical company’s stock, valued at approximately $673,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank increased its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $42,000. Finally, True Wealth Design LLC increased its position in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.5 %

ALNY opened at $244.52 on Friday. The business’s fifty day moving average is $254.70 and its two-hundred day moving average is $261.37. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market cap of $31.65 billion, a price-to-earnings ratio of -112.68 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on ALNY. Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Scotiabank cut their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research report on Friday, February 14th. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Sanford C. Bernstein dropped their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.